Scarica l'app Stockscreener
0.631
1.59%
-0.0102
Dopo l'orario di chiusura:
.65
0.019
+3.01%
Precedente Chiudi:
$0.6412
Aprire:
$0.6521
Volume 24 ore:
609.21K
Relative Volume:
0.56
Capitalizzazione di mercato:
$80.46M
Reddito:
-
Utile/perdita netta:
$-25.91M
Rapporto P/E:
-2.507
EPS:
-0.2517
Flusso di cassa netto:
$-22.73M
1 W Prestazione:
-7.65%
1M Prestazione:
-28.30%
6M Prestazione:
-34.29%
1 anno Prestazione:
-55.56%
Intervallo 1D:
$0.6211
$0.6521
Intervallo di 1 settimana:
$0.6211
$0.718
Portata 52W:
$0.6211
$1.42
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Nome
Oncolytics Biotech Inc
Settore
Industria
Telefono
(403) 670-7377
Indirizzo
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.631 | 87.13M | 0 | -25.91M | -22.73M | -0.2517 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-13 | Iniziato | Lake Street | Buy |
| 2022-10-06 | Iniziato | Maxim Group | Buy |
| 2021-02-17 | Iniziato | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Borsa (ONCY) Ultime notizie
Oncolytics Reports Pelareorep Liver Cancer Research Findings - grafa.com
Form 8K Oncolytics Biotech Inc. For: 29 September By Investing.com - Investing.com South Africa
Oncolytics reports pelareorep data in liver cancer study - Investing.com
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy - GlobeNewswire
Oncolytics Biotech Inc (ONCY) Stock Price Target & Forecast - TradingKey
Form 8K Oncolytics Biotech Inc. For: 28 September By Investing.com - Investing.com Nigeria
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech (ONCY) Advances Clinical Trial for Metastatic Colorectal Cancer Pelareorep Treatment - GuruFocus
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Announces Progress in REO 033 Trial, Site Activations and FDA-Aligned Pathway for Pelareorep in Metastatic Colorectal Cancer - Quiver Quantitative
Oncolytics reports accelerated enrollment, expects Part A interim REO 033 data by year-end 2026 - TradingView
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034 - Yahoo Finance
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Oncolytics Biotech Inc (ONCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oncolytics Biotech (NASDAQ:ONCY) Trading Down 5.2%Time to Sell? - MarketBeat
ONCY Q3 2025 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Misses EPS EstimateEarnings Cycle Outlook - dars.gov.et
Oncolytics Biotech stock lacks a fresh catalyst and stays near $0.77 - AD HOC NEWS
3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets - Yahoo Finance
Oncolytics Biotech Stock Price Forecast. Should You Buy ONCY? - StockInvest.us
Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer - marketscreener.com
Oncolytics Biotech Inc.ADR Key Financial Ratios – Valuation, Profitability & More - Value Research
symbol__ Stock Quote Price and Forecast - CNN
Oncolytics (ONCY) Reports Promising Preclinical Data on Pelareor - GuruFocus
Oncolytics reports preclinical data on pelareorep with RAS inhibitor - investing.com
Oncolytics reports preclinical data on pelareorep with RAS inhibitor By Investing.com - Investing.com India
An experimental cancer treatment combination reduced tumor growth in early tests - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Zacks Research Issues Pessimistic Forecast for ONCY Earnings - MarketBeat
ONCY: FDA Provides Alignment on Registrational Pathway for Pelareorep in CRC - Yahoo Finance
Could Oncolytics Biotech (TSX:ONC) Reach Its Next Clinical Milestone? - Kalkine Media
Can Oncolytics Biotech (TSX:ONC) Unlock Its Next Catalyst? - Kalkine Media
HC Wainwright Has Bearish Estimate for ONCY FY2026 Earnings - MarketBeat
ONCY Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat
H.C. Wainwright cuts Oncolytics Biotech price target to $5 on pipeline shift - Investing.com Canada
H.C. Wainwright Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials - finance.yahoo.com
BRIEF-Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer - Bitget
Oncolytics Biotech (ONCY) Advances Pelareorep Trial with Positiv - GuruFocus
Form 8K Oncolytics Biotech Inc. For: 18 August By Investing.com - Investing.com Nigeria
Oncolytics receives FDA feedback on colorectal cancer study design - Investing.com
Oncolytics receives FDA feedback on colorectal cancer study design By Investing.com - Investing.com Canada
Oncolytics aligns with FDA on potential pivotal expansion of REO 033 in RAS‑mutant MSS colorectal cancer - TradingView
Oncolytics may seek accelerated approval using tumor response data - Stock Titan
Oncolytics Biotech (ONCY) Climbs 4.25% to $0.83 as Small-Cap Biotech Finds BuyersRetracement Entry - vinanet.vn
ONCY Q3 2025 Earnings: Wider Loss Misses Estimates, Stock Still Rises 4.25%Cost Structure Review - vinanet.vn
Oncolytics Biotech (ONCY) Holds Near $0.82 as Shares Edge Up 0.49%Entry Point Alerts - vinanet.vn
Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Oncolytics Biotech Inc Azioni (ONCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Oncolytics Biotech Inc Azioni (ONCY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Mar 12 '26 |
Buy |
0.96 |
5,050 |
4,848 |
114,050 |
| Kelly Jared | Chief Executive Officer |
Feb 12 '26 |
Buy |
0.84 |
29,500 |
24,839 |
109,000 |
| Kelly Jared | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.84 |
5,600 |
4,682 |
79,500 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):